Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07105046

Facilitators and Barriers to Cancer Treatment Among Texas Residents

This trial uses semi-structured interviews and focus groups to determine facilitators and barriers of receiving timely cancer treatment among multiple cancers, across multiple insurance types, throughout Texas

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Cancer Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

The University of Texas M. D. Anderson Cancer Center

Houston, Texas, 77030, United States

Location contact

John Lin, MD

CONTACT

[email protected]

John Lin, MD

PRINCIPAL_INVESTIGATOR

About this study

Primary Objectives:

Aim 1: To comprehensively assess barriers to and facilitators of receiving timely cancer treatment, via in-depth telephone interviews among a purposive sample of Texas patients with Stage I-IV breast, colorectal, lung, and prostate cancer and diverse backgrounds.

Aim 2: To generate consensus on barriers and facilitators, as well as their relative importance, via focus groups, among carefully selected Texas patients with Stage I-IV breast, colorectal, lung and prostate cancer and diverse backgrounds,

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Aims 1 and 2

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  • Verbal consent will be obtained
  • Stated willingness to comply with all study procedures and lifestyle considerations and availability for the duration of the study
  • Males and females; Age ≥ 18 years old
  • Documented diagnosis of breast, colorectal, lung, and prostate cancer patients, stage I-IV
  • Either English or Spanish-speaking

Exclusion criteria

Aims 1 and 2

An individual who meets any of the following criteria will be excluded from participation in this study:

  • Patients who are cognitively impaired
  • Pregnant women

Treatment and study plan

Interviews

Other

A 30 to 45-minute in-depth semi-structured interview by phone will be administer, following a semi-structured interview guide.

Focus groups

Other

45 to 60 minutes video conference

Primary outcomes

  1. 1. Safety and Adverse Events (AEs)

    Time frame: Through study completion; an average of 1 year

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

Study contacts

Contact information is provided by the study sponsor or research team.

John Lin, MD

CONTACT

[email protected]

(832) 729-0382

Sponsors and collaborators

Lead sponsor

M.D. Anderson Cancer Center

Other

Registry information

Important dates

Study start
2026
Primary completion
2026
Study completion
2028
First posted
Aug 5, 2025
Registry last updated
Mar 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.